FIELD: organic chemistry, medicine.
SUBSTANCE: invention relates to 1-ethanolamide PGF2α of formula I 
useful in relaxation of mammalian intraocular pressure. Claimed substance unlike majority of ocular hypotensive prostaglandins doesn't effect through FP-receptor.
EFFECT: new effective compound for relaxation of mammalian intraocular pressure.
4 cl, 1 ex, 16 dwg, 16 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PROSTAGLANDIN FALPHA DERIVATIVES FOR REDUCING INTRAOCULAR PRESSURE | 2018 |
|
RU2718744C2 |
| DERIVATIVES OF PROSTAGLANDINS WITHOUT ADVERSE EFFECTS FOR GLAUCOMA TREATMENT | 1998 |
|
RU2207858C2 |
| PROTECTIVE MEDICIATION FOR RETINA NEURON WHICH CONTAINS AS ACTIVE COMPONETS PROSTAGLANDIN F2α DERIVATIVE | 2006 |
|
RU2414904C2 |
| PHARMACEUTICAL COMPOSITION OF TAFLUPROST | 2021 |
|
RU2761625C2 |
| INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
| INTRACHAMBER IMPLANTS WITH PROLONGED RELEASE OF THERAPEUTIC AGENT | 2011 |
|
RU2565445C2 |
| METHOD OF TREATING ELEVATED INTRAOCULAR PRESSURE USING INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEM | 2014 |
|
RU2664686C2 |
| METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION | 2010 |
|
RU2548762C2 |
| PAI-1 BINDING MODULATORS FOR TREATMENT OF EYE DISEASES | 2007 |
|
RU2465898C2 |
| HYDROXYTRIAZINE COMPOUND AND ITS APPLICATION FOR MEDICAL PURPOSES | 2016 |
|
RU2772907C2 |
